Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released an in-depth report, Bladder Cancer – Global Clinical Trial Landscape 2024, offering key insights for stakeholders across the oncology and clinical research sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241120379204/en/
Bladder cancer remains a significant health challenge worldwide, with over 614,000 new cases and 220,600 deaths recorded in 2022. Novotech’s latest report provides a detailed examination of the evolving landscape in bladder cancer research, with a focus on clinical trial trends, emerging therapeutic strategies, and regional variations in patient outcomes.
Key Highlights from the Report:
- Bladder Cancer Statistics: A thorough analysis of incidence and survival data, highlighting that Europe and Asia account for the majority of global cases.
- Clinical Trial Landscape: An overview of over 1,500 bladder cancer clinical trials initiated since 2019, with North America, Asia-Pacific, and Europe leading in trial volume.
- Advancements in Treatment: Exploration of innovative therapies, including immunotherapy, targeted treatments, and combination therapies, which are opening new avenues in bladder cancer care.
- Future Projections: Bladder cancer cases are projected to exceed 1.2 million annually by 2050, underscoring the urgent need for advanced treatment options and accessible healthcare solutions.
This report explores valuable information for biotech professionals, oncologists, researchers and scientists. By examining trial density, recruitment efficiencies, and regional disparities in treatment outcomes, the report provides actionable insights for those aiming to enhance the efficiency and effectiveness of bladder cancer trials.
To access the full report and gain a deeper understanding of the trends shaping bladder cancer research, download the report here.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120379204/en/
Contact details:
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
